Pharmaessentia Corp., of Taiwan, and Kinex Pharmaceuticals Inc., of Buffalo, N.Y., said they executed a new licensing agreement granting Pharmaessentia exclusive development and commercial rights to Oraxol and Oratecan in Taiwan and Singapore. Kinex will receive an undisclosed up-front payment, milestones and royalties, and Pharmaessentia also agreed to conduct clinical studies in Taiwan to contribute to the global registration programs for the drugs.